Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy
Stopped early · Phase 1/Phase 2
Conditions studied: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
In brief
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Tretinoin may help hematologic cancer cells develop into normal white blood cells. PURPOSE: Phase I/II trial to study the effectiveness of arsenic trioxide with or without tretinoin in treating patients who have hematologic cancer that has not responded to previous therapy.
Key facts
- Study ID
- NCT00006220
- Run by
- Washington University School of Medicine
- People needed
- 5
- Starts
- 1999-06-01
- Expected to finish
- 2002-02-01
- Last updated by the study team
- 2013-02-06
Who can join
Age: 15 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Washington University Barnard Cancer Center — St Louis, Missouri, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.